Weiss Multi Strategy Advisers LLC Vertex Pharmaceuticals Inc Transaction History

Weiss Multi Strategy Advisers LLC

$0
Q1 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$343.0 - $410.68 $4.19 Million - $5.02 Million	-12,223 Reduced 29.38%	29,375 $12 Million
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $5.79 Million - $6.21 Million	-17,120 Reduced 29.16%	41,598 $14.5 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $2.02 Million - $2.26 Million	-6,419 Reduced 9.85%	58,718 $20.7 Million
Q1 2023 May 15, 2023	BUY	$283.23 - $323.1 $10.5 Million - $12 Million	37,235 Added 133.45%	65,137 $20.5 Million
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $1.71 Million - $1.92 Million	-5,969 Reduced 17.62%	27,902 $8.06 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $1.66 Million - $1.85 Million	-6,050 Reduced 15.15%	33,871 $9.81 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $371,001 - $461,936	-1,579 Reduced 3.8%	39,921 $11.2 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $706,994 - $833,277	-3,193 Reduced 7.14%	41,500 $10.8 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $1.85 Million - $2.34 Million	-10,456 Reduced 18.96%	44,693 $9.82 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $566,662 - $634,140	3,124 Added 6.0%	55,149 $10 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $376,292 - $443,747	2,007 Added 4.01%	52,025 $10.5 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $1.96 Million - $2.29 Million	9,491 Added 23.42%	50,018 $10.7 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $643,801 - $858,639	3,110 Added 8.31%	40,527 $9.58 Million
Q3 2020 Nov 16, 2020	SELL	$255.65 - $303.1 $123,223 - $146,094	-482 Reduced 1.27%	37,417 $10.2 Million
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $293,574 - $385,131	1,302 Added 3.56%	37,899 $11 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $280,277 - $347,677	-1,403 Reduced 3.69%	36,597 $8.71 Million
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $1.17 Million - $1.57 Million	7,000 Added 22.58%	38,000 $8.32 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $664,920 - $748,360	-4,000 Reduced 11.43%	31,000 $5.25 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $823,050 - $951,850	-5,000 Reduced 12.5%	35,000 $6.42 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $2.16 Million - $2.73 Million	-14,208 Reduced 26.21%	40,000 $6.63 Million
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $88,896 - $102,152	-530 Reduced 0.97%	54,208 $10.4 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $690,421 - $805,270	4,738 Added 9.48%	54,738 $9.3 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $151,600 - $177,130	-1,000 Reduced 1.96%	50,000 $8.15 Million
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $274,560 - $311,100	-2,000 Reduced 3.77%	51,000 $7.64 Million
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $7.85 Million - $8.6 Million	53,000	53,000 $8.06 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$11 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$9.51 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$8.75 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$4.85 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$3.7 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Weiss Multi Strategy Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Weiss Multi Strategy Advisers LLC with notifications on news.

Account